TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific, and clinical updates across its development pipeline. The presentation will be anchored by the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include portfolio updates and discussion of its broader investment thesis.
The webcast highlights TransCode's focus on advancing its lead therapeutic candidate, TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. This program is particularly significant for patients with high-risk and advanced cancers, as the company aims to address unmet medical needs in oncology. The Phase 2a trial in colorectal cancer marks a critical step in evaluating the efficacy of TTX-MC138 in a specific patient population.
Investors and industry observers will be watching closely for updates on the trial's progress and the company's broader pipeline, which includes other first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells. The webcast is expected to provide insights into TransCode's strategic direction and the potential impact of its RNA-based therapeutics.
For more details, the full press release is available at this link. Latest news and updates on RNAZ can be found in the company's newsroom at https://ibn.fm/RNAZ.
